The LEADER trial demonstrated cardiovascular benefit comparable to what semaglutide would later show in SUSTAIN-6, though with a somewhat smaller magnitude of effect
Matsumura K, Miki T, Jhomori T, Gonoi T, and Seino S
Support healthy cortisol balance
Participants receiving semaglutide 7.2 mg achieved 20.7% average weight reduction, with 33% of patients losing more than 25% of their body weight ^1
reuteri decreased repetitive behaviors and increased GABA receptor gene expression (GABRA1, GABRA3, and GABRB1) as well as protein levels (GABRA1) in the hippocampus and prefrontal cortex (PFC) of Shank3 mutant mice, a model of ASD
7 Elucidating structural determinants determining ZZ1s bromodomain selectivity